| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals, Inc. | 44.07B | 332.92 | 142.88 | 65.19% | 8.45% | 39.76% | 1.06% | 3.76 |
| SLXNWSilexion Therapeutics Ltd. | 63.6M | 0.03 | 0.00 | -132.54% | ||||
| EDITEditas Medicine, Inc. | 205.18M | 2.20 | -0.76 | -58.64% | -430.84% | -14.85% | 0.26 | |
| SGMOSangamo Therapeutics, Inc. | 92.01M | 0.43 | -0.88 | -67.2% | -331.28% | -17.44% | 1.34 | |
| CAMPCAMP4 Therapeutics Corporation | 210.49M | 4.49 | -1.69 | 86.29% | -14.04% | -133.54% | 0.14 | |
| SLNSilence Therapeutics plc | 256.95M | 5.44 | -1.71 | 70.47% | -252.16% | -84.61% | 0.00 | |
| PEPGPepGen Inc. | 202.89M | 6.22 | -2.18 | -57.35% | 0.16 | |||
| ARCTArcturus Therapeutics Holdings Inc. | 224.14M | 8.23 | -2.74 | -12.27% | -72.48% | -29.71% | 0.12 |
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 25K |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | -25K |
| Gross Margin % | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - |
| Operating Expenses | 195.86K | 943.93K | 1.23M | 4.68M | 12.55M |
| OpEx % of Revenue | - | - | - | - | - |
| Selling, General & Admin | 195.86K | 943.93K | 1.23M | 928K | 6.73M |
| SG&A % of Revenue | - | - | - | - | - |
| Research & Development | 0 | 0 | 0 | 3.71M | 5.82M |
| R&D % of Revenue | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 45K | 0 |
| Operating Income | -195.86K | -943.93K | -1.23M | -4.68M | -12.57M |
| Operating Margin % | - | - | - | - | - |
| Operating Income Growth % | - | -381.94% | -30.55% | -279.85% | -168.55% |
| EBITDA | -195.86K | -755.22K | 584.02K | -4.64M | -12.55M |
| EBITDA Margin % | - | - | - | - | - |
| EBITDA Growth % | - | -285.59% | 177.33% | -893.8% | -170.62% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 45K | 25K |
| EBIT | -195.86K | -755.22K | 584.02K | -4.68M | -16.46M |
| Net Interest Income | 0 | 6.37K | 1.69M | 144K | -51K |
| Interest Income | 0 | 6.37K | 1.69M | 153K | 1K |
| Interest Expense | 0 | 0 | 0 | 9K | 52K |
| Other Income/Expense | 0 | 188.72K | 1.82M | -395K | -3.94M |
| Pretax Income | -195.86K | -755.22K | 584.02K | -5.08M | -16.51M |
| Pretax Margin % | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 32K | 10K |
| Effective Tax Rate % | 100% | 100% | 100% | 97.36% | 99.6% |
| Net Income | -195.86K | -755.22K | 584.02K | -4.94M | -16.44M |
| Net Margin % | - | - | - | - | - |
| Net Income Growth % | - | -285.59% | 177.33% | -946.2% | -232.72% |
| Net Income (Continuing) | -195.86K | -755.22K | 584.02K | -5.11M | -16.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 3.59M | 3.42M | 0 |
| EPS (Diluted) | -0.12 | -0.46 | 0.35 | 0.39 | 25.49 |
| EPS Growth % | - | -283.33% | 176.09% | 11.43% | 6435.9% |
| EPS (Basic) | -0.12 | -0.46 | 0.35 | 0.39 | 25.49 |
| Diluted Shares Outstanding | 1.65M | 1.65M | 1.67M | 681.09K | 623.85K |
| Basic Shares Outstanding | 1.65M | 1.65M | 1.67M | 681.09K | 623.85K |
| Dividend Payout Ratio | - | - | - | - | - |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 51.7K | 407.8K | 8.84M | 4.98M | 2.25M |
| Cash & Short-Term Investments | 51.7K | 38.94K | 8.26M | 4.59M | 1.19M |
| Cash Only | 51.7K | 38.94K | 8.26M | 4.59M | 1.19M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 67K | 49K | 97K |
| Total Non-Current Assets | 77.7K | 115.01M | 494K | 277K | 613K |
| Property, Plant & Equipment | 0 | 0 | 464K | 247K | 560K |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 115.01M | 0 | 0 | 48K |
| Other Non-Current Assets | 77.7K | 0 | 30K | 30K | 5K |
| Total Assets | 129.4K | 115.41M | 9.33M | 5.26M | 2.86M |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | - | 89092.47% | -91.91% | -43.68% | -45.53% |
| Total Current Liabilities | 29.4K | 348.58K | 1.61M | 2.2M | 3.52M |
| Accounts Payable | 0 | 0 | 240K | 319K | 929K |
| Days Payables Outstanding | - | - | - | - | 13.56K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 1M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 29.4K | 348.58K | 256K | 407K | 790K |
| Current Ratio | 1.76x | 1.17x | 5.49x | 2.27x | 0.64x |
| Quick Ratio | 1.76x | 1.17x | 5.49x | 2.27x | 0.64x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 269.99K | 160.34K | 14.8M | 15.12M | 3.33M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 2.96M |
| Capital Lease Obligations | 0 | 0 | 156K | 59K | 368K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 269.99K | 160.34K | 14.65M | 15.06M | 0 |
| Total Liabilities | 299.39K | 508.92K | 16.41M | 17.31M | 6.85M |
| Total Debt | 0 | 0 | 271K | 171K | 4.49M |
| Net Debt | -51.7K | -38.94K | -7.99M | -4.42M | 3.3M |
| Debt / Equity | - | - | - | - | - |
| Debt / EBITDA | - | - | 0.46x | - | - |
| Net Debt / EBITDA | - | - | -13.68x | - | - |
| Interest Coverage | - | - | - | -520.11x | -241.75x |
| Total Equity | -169.99K | 114.91M | -7.08M | -12.06M | -3.99M |
| Equity Growth % | - | 67695.3% | -106.16% | -70.31% | 66.91% |
| Book Value per Share | -0.10 | 69.60 | -4.23 | -17.70 | -6.39 |
| Total Shareholders' Equity | -169.99K | 114.91M | -10.66M | -15.48M | -3.99M |
| Common Stock | 298 | 115M | 1K | 1K | 2K |
| Retained Earnings | -195.86K | -951.08K | -21.87M | -26.81M | -43.25M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 3.59M | 3.42M | 0 |
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -75K | -1.41M | -3.33M | -4.53M | -8.4M |
| Operating CF Margin % | - | - | - | - | - |
| Operating CF Growth % | - | -1776.31% | -136.99% | -35.8% | -85.38% |
| Net Income | -195.86K | -755.22K | -3.49M | -5.11M | -16.52M |
| Depreciation & Amortization | 0 | 0 | 57K | 45K | 25K |
| Stock-Based Compensation | 0 | 0 | 125K | 130K | 5.86M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -182.34K | -268K | 317K | 3.82M |
| Working Capital Changes | 120.86K | -469.68K | 239K | 87K | -1.58M |
| Change in Receivables | 0 | 0 | -40K | 18K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | -38K | 79K | 610K |
| Cash from Investing | 0 | 0 | -524K | 573K | -22K |
| Capital Expenditures | 0 | 0 | -40K | -12K | -22K |
| CapEx % of Revenue | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 78K | 0 |
| Cash from Financing | 126.7K | 116.4M | 2.75M | 522K | 5.1M |
| Debt Issued (Net) | 149.99K | 150.01K | 0 | 0 | -250K |
| Equity Issued (Net) | -23.29K | 1000K | 1000K | 522K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -2.55M | 3K | 0 | 2.3M |
| Net Change in Cash | 51.7K | -12.76K | -1.77M | -3.66M | -3.38M |
| Free Cash Flow | -75K | -1.41M | -3.38M | -4.54M | -8.42M |
| FCF Margin % | - | - | - | - | - |
| FCF Growth % | - | -1776.32% | -139.83% | -34.55% | -85.38% |
| FCF per Share | -0.05 | -0.85 | -2.02 | -6.67 | -13.49 |
| FCF Conversion (FCF/Net Income) | 0.38x | 1.86x | -5.71x | 0.92x | 0.51x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -1.32% | 1.08% | - | - |
| Return on Invested Capital (ROIC) | - | -1.23% | -1.85% | - | - |
| Interest Coverage | - | - | - | -520.11x | -241.75x |
| FCF Conversion | 0.38x | 1.86x | -5.71x | 0.92x | 0.51x |
Explore detailed financial history, valuation models, and returns analysis
DCF models, peer multiples & analyst estimates
Historical returns with dividends reinvested
Yield, growth, payout safety & DRIP calculator
EPS trends, net income & profitability analysis
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of valuation, profitability & efficiency metrics